bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
199 hedge funds and large institutions have $2.88B invested in bluebird bio in 2016 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 90 increasing their positions, 58 reducing their positions, and 30 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
55% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 58
14% more call options, than puts
Call options by funds: $50.2M | Put options by funds: $44M
8.87% more ownership
Funds ownership: 0% → 8.87% (+8.9%)
3% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 30
1% less funds holding
Funds holding: 200 → 199 (-1)
4% less capital invested
Capital invested by funds: $3.01B → $2.88B (-$134M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$66.6M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$44.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$31.5M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$20.7M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$20.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$55.3M |
| 2 |
Millennium Management
New York
|
-$44.3M |
| 3 |
PC
Passport Capital
San Francisco,
California
|
-$19.6M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$14.5M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$12.8M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
226
US Bancorp
Minneapolis,
Minnesota
| – | -$79K | -90 | Closed |
|
|
QT
227
Quantbot Technologies
New York
| – | -$7K | -9 | Closed |
|
|
EFSCE
228
Enterprise Financial Services Corp (EFSC)
Clayton,
Missouri
| – | -$3K | -4 | Closed |
|
229
AssetMark Inc
Concord,
California
| – | -$1K | -1 | Closed |
|
BLUE Hedge Fund Activity: Q4 2016 in Review
199 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q4 2016, worth a combined $2.88B — down 4.4% from $3.01B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new BLUE positions and 30 closed out — a net gain of 1 holder — while 90 added to existing stakes and 58 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $66.6M. The largest seller was OrbiMed, cutting an estimated $55.3M.
- 199 institutional investors held bluebird bio (BLUE) as of Q4 2016, down from 200 in Q3 2016.
- Funds reported $2.88B of bluebird bio stock for Q4 2016, down 4.4% quarter-over-quarter.
- 31 funds opened new bluebird bio positions in Q4 2016 and 30 closed out, a net change of +1 holder.
- The largest bluebird bio buyer in Q4 2016 was Wellington Management Group, an estimated $66.6M added.
- The largest bluebird bio seller in Q4 2016 was OrbiMed, an estimated $55.3M sold.
Based on aggregated 13F filings for Q4 2016.